STOCK TITAN

Macrogenics Inc - MGNX STOCK NEWS

Welcome to our dedicated news page for Macrogenics (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Macrogenics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Macrogenics's position in the market.

Rhea-AI Summary
MacroGenics, Inc. provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer. Early interim safety data was compared to Phase 1 data, with plans for updated data by May 31 and additional clinical data in Fall 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.07%
Tags
-
Rhea-AI Summary
MacroGenics, Inc. (NASDAQ: MGNX) provides updates on recent corporate progress, including the presentation of preliminary data from the TAMARACK Phase 2 study of vobra duo in mCRPC patients at ASCO 2024. The company also initiates a Phase 1 study of MGC026, its first topoisomerase I inhibitor-based ADC. Preclinical data on two ADC product candidates, MGC026 and MGC028, will be presented at AACR. A conference call is scheduled to discuss these developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.02%
Tags
-
Rhea-AI Summary
MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in investor conferences in March 2024, including TD Cowen’s 44th Annual Health Care Conference, Leerink Partners 2024 Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference. The President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will be actively involved in various discussions and meetings during these events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.71%
Tags
conferences
Rhea-AI Summary
MacroGenics, Inc. (MGNX) will release its Q4 2023 financial results on March 7, 2024. The company focuses on developing antibody-based therapeutics for cancer treatment. A conference call discussing financial results and corporate progress will be held on the same day at 4:30 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Summary
MacroGenics, Inc. (MGNX) announced their participation in the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York. The company's President and CEO, Scott Koenig, M.D., Ph.D., will take part in a fireside chat on February 7, 2024, at 2:00 pm ET. The management will also engage in one-on-one meetings. The webcast of the presentation can be accessed on the company's Investor Relations website, with an archived replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
MacroGenics, Inc. (MGNX) to participate in the 42nd Annual J.P. Morgan Healthcare Conference with President & CEO, Scott Koenig, M.D., Ph.D., providing a corporate overview on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
conferences
Rhea-AI Summary
MacroGenics, Inc. provides an update on recent corporate progress and reports financial results for Q3 2023. The company has received $335 million in non-dilutive capital and extended its cash runway into 2026. Multiple data read-outs are expected in the next two years, including results from the TAMARACK study of vobra duo in metastatic castration-resistant prostate cancer. Other updates include progress on various investigational programs and a milestone payment from Gilead Sciences. The company's cash, cash equivalents, and marketable securities balance is $256.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.1%
Tags
-
Rhea-AI Summary
MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in upcoming investor conferences: BMO Biopharma Spotlight Series: Oncology Day on November 8, Stifel 2023 Healthcare Conference on November 14, and 6th Annual Evercore ISI HealthCONx Conference on November 28. Webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences
-
Rhea-AI Summary
MacroGenics, Inc. will release its financial results for Q3 2023 on November 6, 2023. The company is focused on developing antibody-based therapeutics for cancer treatment. A conference call will be held on the same day to discuss the financial results and recent corporate progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
Rhea-AI Summary
MacroGenics announces nomination of research program by Gilead Sciences, receiving $15 million and potential for $1.7 billion in milestones and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
Macrogenics Inc

Nasdaq:MGNX

MGNX Rankings

MGNX Stock Data

1.10B
52.17M
2.61%
99.85%
10.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About MGNX

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!